Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Analysis By Product (Corticosteroids, Intravenous Immunoglobulin, Anti-D Immunoglobulin, TPO-RA) And Segment Forecasts To 2020
Global ITP therapeutics market is expected to reach USD 566.37 million by 2020. Introduction of new drugs especially pertaining to TPO-RA and IVIG classes is expected to serve this market as a high impact rendering driver. Presence of favorable government regulations such as the Orphan Drug Act in the U.S. aimed at encouraging new product development is expected to have a positive impact on the market. Most notable trend observed in this market is an increase in demand for combination therapies involving two or more drugs. Clinical evidences suggest that some combination therapies prove to be cost effective, exhibit higher efficacies and help curb side effects otherwise associated with individual therapeutic classes.
Corticosteroids are the most frequently administered therapy for idiopathic thrombocytopenic purpura (ITP). The global corticosteroids market for ITP was valued at over USD 125.0 million in 2013. Corticosteroids are considered as the first line of treatment in patients with ITP and therefore, enjoy very high usage rates.
Further key findings from the study suggest:
TPO-RA is the most lucrative segment of this market and is expected to witness a surge in demand owing to the potential commercialization of Avatrombopag in 2015. Moreover, the ability of this class to cater to splenectomized patients witnessing relapses attributes to such rapid growth.
North America accounted for over 40% of the global ITP market revenue in 2013, on account of high market penetration rates and favorable regulations. Presence of an extensive number of clinical trial studies related to combination therapy and new product development is also expected to drive regional growth during the forecast period.
Europe was the second largest regional ITP therapeutics market in 2013 and is expected to maintain its position over the forecast period. High product usage rates and the presence of government initiatives granting special status to orphan drugs are some factors accounting for its large market share.
Asia Pacific is expected to present high future growth potential over the next six years, owing to the presence of large untapped opportunities in the emerging markets of India and China. Presence of favorable government initiatives and sophisticated healthcare infrastructure in Japan and Australia are also expected to attribute to its market attractiveness.
Key players of the ITP therapeutics market include GSK, Amgen Inc., Grifols Biologicals Inc., Eisai and F.Hoffman-La Roche.
For the purpose of this study, Grand View Research has segmented the global ITP therapeutics market on the basis of product and region:
Global ITP Therapeutics Product Outlook (Revenue, USD Million, 2012 – 2020)
Corticosteroids are the most frequently administered therapy for idiopathic thrombocytopenic purpura (ITP). The global corticosteroids market for ITP was valued at over USD 125.0 million in 2013. Corticosteroids are considered as the first line of treatment in patients with ITP and therefore, enjoy very high usage rates.
Further key findings from the study suggest:
TPO-RA is the most lucrative segment of this market and is expected to witness a surge in demand owing to the potential commercialization of Avatrombopag in 2015. Moreover, the ability of this class to cater to splenectomized patients witnessing relapses attributes to such rapid growth.
North America accounted for over 40% of the global ITP market revenue in 2013, on account of high market penetration rates and favorable regulations. Presence of an extensive number of clinical trial studies related to combination therapy and new product development is also expected to drive regional growth during the forecast period.
Europe was the second largest regional ITP therapeutics market in 2013 and is expected to maintain its position over the forecast period. High product usage rates and the presence of government initiatives granting special status to orphan drugs are some factors accounting for its large market share.
Asia Pacific is expected to present high future growth potential over the next six years, owing to the presence of large untapped opportunities in the emerging markets of India and China. Presence of favorable government initiatives and sophisticated healthcare infrastructure in Japan and Australia are also expected to attribute to its market attractiveness.
Key players of the ITP therapeutics market include GSK, Amgen Inc., Grifols Biologicals Inc., Eisai and F.Hoffman-La Roche.
For the purpose of this study, Grand View Research has segmented the global ITP therapeutics market on the basis of product and region:
Global ITP Therapeutics Product Outlook (Revenue, USD Million, 2012 – 2020)
- Corticosteroids
- Intravenous Immunoglobulin (IVIG)
- Anti-D Immunoglobulin
- Thrombopoietin Receptor Agonists (TPO-RA)
- Others
- North America
- U.S.
- Mexico
- Europe
- Germany
- UK
- Asia Pacific
- India
- Japan
- China
- RoW
- Brazil
CHAPTER 1 EXECUTIVE SUMMARY
CHAPTER 2 ITP THERAPEUTICS INDUSTRY OUTLOOK
2.1 Market Segmentation
2.2 Market Size and Growth Prospects
2.3 Market Dynamics
2.3.1 Market Driver Analysis
2.3.1.1 Presence of favorable government initiatives
2.3.1.2 Growing demand for combination therapies and new product development
2.3.1.3 Presence of co-existing conditions inducing ITP
2.3.2 Market Restraint Analysis
2.3.2.1 Availability of external product substitutes
2.3.2.2 Associated risks resulting in product withdrawal
2.4 Key Opportunities Prioritized
2.5 Industry Analysis - Porter's
2.6 ITP Therapeutics – PESTEL Analysis
2.7 Combination Therapy for ITP
2.7.1 Combination of IVIG with oral corticosteroids
2.7.1.1 IVIG With High Dose Methylprednisolone
2.7.1.2 Combination of IVIG and prednisolone
2.7.2 Combination of corticosteroids and monoclonal antibodies
2.7.2.1 Dexamethasone with rituximab (Mabthera)
2.7.2.2 Combination of rituximab with cyclophosphamide, vincristine and prednisone
2.7.3 Combination of immunosuppressant therapy
2.7.3.1 Combination of azathioprine, danzol or mycophenolate mofetil
2.7.3.2 Combination of vincristine, methylprednisolone and cyclosporine
2.7.4 Combination of monoclonal antibodies
2.7.5 Combination of TPO-RA and corticosteroids
2.7.6 Combination of recombinant human thrombopoietin with Rituximab
2.7.7 Combination of cyclosporine, romiplostim and IVIG
2.8 Splenectomy and its effect on the overall market
2.8.1 Introduction
2.8.2 Impact of splenectomy on product segments
2.9 Pipeline Drugs
2.9.1 IVIG pipeline
2.9.2 TPO-RA pipeline
2.9.3 Other classes
2.9.4 Combination therapy pipeline
CHAPTER 3 ITP THERAPEUTICS PRODUCT OUTLOOK
3.1 ITP therapeutics market share by product, 2013 & 2020
3.2 Corticosteroids
3.2.1 Corticosteroids for ITP market, 2012 – 2020 (USD Million)
3.3 IVIG or IVIg
3.3.1 IVIG for ITP market, 2012 – 2020 (USD Million)
3.4 Anti-D Immunoglobulin
3.4.1 Anti-D for ITP market, 2012 – 2020 (USD Million)
3.4.1.1 Thrombopoietin receptor agonists (TPO-RA)
3.4.2 TPO-RA for ITP market, 2012 – 2020 (USD Million)
3.5 Others
3.5.1 Monoclonal antibody therapy (qualitative analysis)
3.5.2 Immunosuppressant therapy (qualitative analysis)
3.5.3 Cyclosporine (qualitative analysis)
3.5.4 Platelets clearance inhibitors (qualitative analysis)
3.5.5 Vinca alkaloids (qualitative analysis)
3.5.6 Stem cell transplantation (qualitative analysis)
3.5.7 Others therapies for ITP market, 2012 – 2020 (USD Million)
CHAPTER 4 ITP REGIONAL OUTLOOK
4.1 ITP therapeutics market share, by region, 2013 & 2020
4.2 North America
4.2.1 North America ITP therapeutics market, 2012 - 2020 (USD Million)
4.2.2 U.S.
4.2.3 Mexico ITP therapeutics market, by product, 2012 – 2020 (USD Million)
4.3 Europe
4.3.1 Europe ITP therapeutics market, 2012 - 2020 (USD Million)
4.3.2 Germany ITP therapeutics market, by product, 2012 – 2020 (USD Million)
4.3.3 UK ITP therapeutics market, by product, 2012 – 2020 (USD Million)
4.4 Asia Pacific
4.4.1 Asia Pacific ITP therapeutics market, 2012 - 2020 (USD Million)
4.4.2 India ITP therapeutics market, 2012 – 2020, by product
4.4.3 Japan ITP therapeutics market, product, 2012 – 2020 (USD Million)
4.4.4 China
4.5 RoW
4.5.1 Row ITP therapeutics market, 2012 - 2020 (USD Million)
4.5.2 Brazil ITP therapeutics market, by product, 2012 – 2020 (USD million)
CHAPTER 5 COMPETITIVE LANDSCAPE
5.1 Amgen.
5.1.1 Company Overview
5.1.2 Financial Performance
5.1.3 Product Benchmarking
5.1.4 Strategic Initiatives
5.2 F. Hoffman-La Roche AG
5.2.1 Company Overview
5.2.2 Financial Performance
5.2.3 Product Benchmarking
5.2.4 Strategic Initiatives
5.3 Grifols Biologicals Inc.
5.3.1 Company Overview
5.3.2 Financial Performance
5.3.3 Product Benchmarking
5.3.4 Strategic Initiatives
5.4 GlaxoSmithKline (GSK).
5.4.1 Company Overview
5.4.2 Financial Performance
5.4.3 Product Benchmarking
5.4.4 Strategic Initiatives
CHAPTER 6 METHODOLOGY AND SCOPE
6.1 Research Methodology
6.2 Research Scope & Assumptions
6.3 List of Data Sources
CHAPTER 2 ITP THERAPEUTICS INDUSTRY OUTLOOK
2.1 Market Segmentation
2.2 Market Size and Growth Prospects
2.3 Market Dynamics
2.3.1 Market Driver Analysis
2.3.1.1 Presence of favorable government initiatives
2.3.1.2 Growing demand for combination therapies and new product development
2.3.1.3 Presence of co-existing conditions inducing ITP
2.3.2 Market Restraint Analysis
2.3.2.1 Availability of external product substitutes
2.3.2.2 Associated risks resulting in product withdrawal
2.4 Key Opportunities Prioritized
2.5 Industry Analysis - Porter's
2.6 ITP Therapeutics – PESTEL Analysis
2.7 Combination Therapy for ITP
2.7.1 Combination of IVIG with oral corticosteroids
2.7.1.1 IVIG With High Dose Methylprednisolone
2.7.1.2 Combination of IVIG and prednisolone
2.7.2 Combination of corticosteroids and monoclonal antibodies
2.7.2.1 Dexamethasone with rituximab (Mabthera)
2.7.2.2 Combination of rituximab with cyclophosphamide, vincristine and prednisone
2.7.3 Combination of immunosuppressant therapy
2.7.3.1 Combination of azathioprine, danzol or mycophenolate mofetil
2.7.3.2 Combination of vincristine, methylprednisolone and cyclosporine
2.7.4 Combination of monoclonal antibodies
2.7.5 Combination of TPO-RA and corticosteroids
2.7.6 Combination of recombinant human thrombopoietin with Rituximab
2.7.7 Combination of cyclosporine, romiplostim and IVIG
2.8 Splenectomy and its effect on the overall market
2.8.1 Introduction
2.8.2 Impact of splenectomy on product segments
2.9 Pipeline Drugs
2.9.1 IVIG pipeline
2.9.2 TPO-RA pipeline
2.9.3 Other classes
2.9.4 Combination therapy pipeline
CHAPTER 3 ITP THERAPEUTICS PRODUCT OUTLOOK
3.1 ITP therapeutics market share by product, 2013 & 2020
3.2 Corticosteroids
3.2.1 Corticosteroids for ITP market, 2012 – 2020 (USD Million)
3.3 IVIG or IVIg
3.3.1 IVIG for ITP market, 2012 – 2020 (USD Million)
3.4 Anti-D Immunoglobulin
3.4.1 Anti-D for ITP market, 2012 – 2020 (USD Million)
3.4.1.1 Thrombopoietin receptor agonists (TPO-RA)
3.4.2 TPO-RA for ITP market, 2012 – 2020 (USD Million)
3.5 Others
3.5.1 Monoclonal antibody therapy (qualitative analysis)
3.5.2 Immunosuppressant therapy (qualitative analysis)
3.5.3 Cyclosporine (qualitative analysis)
3.5.4 Platelets clearance inhibitors (qualitative analysis)
3.5.5 Vinca alkaloids (qualitative analysis)
3.5.6 Stem cell transplantation (qualitative analysis)
3.5.7 Others therapies for ITP market, 2012 – 2020 (USD Million)
CHAPTER 4 ITP REGIONAL OUTLOOK
4.1 ITP therapeutics market share, by region, 2013 & 2020
4.2 North America
4.2.1 North America ITP therapeutics market, 2012 - 2020 (USD Million)
4.2.2 U.S.
4.2.3 Mexico ITP therapeutics market, by product, 2012 – 2020 (USD Million)
4.3 Europe
4.3.1 Europe ITP therapeutics market, 2012 - 2020 (USD Million)
4.3.2 Germany ITP therapeutics market, by product, 2012 – 2020 (USD Million)
4.3.3 UK ITP therapeutics market, by product, 2012 – 2020 (USD Million)
4.4 Asia Pacific
4.4.1 Asia Pacific ITP therapeutics market, 2012 - 2020 (USD Million)
4.4.2 India ITP therapeutics market, 2012 – 2020, by product
4.4.3 Japan ITP therapeutics market, product, 2012 – 2020 (USD Million)
4.4.4 China
4.5 RoW
4.5.1 Row ITP therapeutics market, 2012 - 2020 (USD Million)
4.5.2 Brazil ITP therapeutics market, by product, 2012 – 2020 (USD million)
CHAPTER 5 COMPETITIVE LANDSCAPE
5.1 Amgen.
5.1.1 Company Overview
5.1.2 Financial Performance
5.1.3 Product Benchmarking
5.1.4 Strategic Initiatives
5.2 F. Hoffman-La Roche AG
5.2.1 Company Overview
5.2.2 Financial Performance
5.2.3 Product Benchmarking
5.2.4 Strategic Initiatives
5.3 Grifols Biologicals Inc.
5.3.1 Company Overview
5.3.2 Financial Performance
5.3.3 Product Benchmarking
5.3.4 Strategic Initiatives
5.4 GlaxoSmithKline (GSK).
5.4.1 Company Overview
5.4.2 Financial Performance
5.4.3 Product Benchmarking
5.4.4 Strategic Initiatives
CHAPTER 6 METHODOLOGY AND SCOPE
6.1 Research Methodology
6.2 Research Scope & Assumptions
6.3 List of Data Sources
LIST OF TABLES
1. ITP Therapeutics Market – Industry Summary & Critical Success Factors (CSFs)
2. ITP therapeutics market, by product, 2012 – 2020 (USD Million)
3. ITP Therapeutics market, by region, 2012 – 2020 (USD Million)
4. ITP Therapeutics – Key market driver analysis
5. Orphan drug policies, by country
6. ITP prevalence, by condition
7. ITP Therapeutics – Key market restraint analysis
8. Side effects, by class
9. Dosage information: IVIG and IVIG with high dose methylprednisolone
10. Comparative analysis: Dexamethasone and Dexamethasone with rituximan
11. Impact of splenectomy on product segments
12. List of major brands and generic names of corticosteroids for ITP
13. Brands and generic names of IVIG for ITP
14. List of major brands and generic names of anti-D for ITP
15. North America ITP therapeutics market, by product, 2012 – 2020 (USD Million)
16. U.S. ITP therapeutics market, by product, 2012 – 2020 (USD Million)
17. Mexico ITP therapeutics market, by product, 2012 – 2020 (USD Million)
18. Access to orphan drugs in European countries (key countries)
19. Europe ITP therapeutics market, by product, 2012 – 2020 (USD Million)
20. Germany ITP therapeutics market, by product, 2012 – 2020 (USD Million)
21. U.K ITP therapeutics market, by product, 2012 – 2020 (USD Million)
22. Asia Pacific ITP therapeutics market, by product, 2012 – 2020 (USD Million)
23. India ITP therapeutics market, by product, 2012 – 2020 (USD Million)
24. Japan ITP therapeutics market, by product, 2012 – 2020 (USD Million)
25. China ITP therapeutics market, by product, 2012 – 2020 (USD Million)
26. Brazil ITP therapeutics market, by product, 2012 – 2020 (USD Million)
1. ITP Therapeutics Market – Industry Summary & Critical Success Factors (CSFs)
2. ITP therapeutics market, by product, 2012 – 2020 (USD Million)
3. ITP Therapeutics market, by region, 2012 – 2020 (USD Million)
4. ITP Therapeutics – Key market driver analysis
5. Orphan drug policies, by country
6. ITP prevalence, by condition
7. ITP Therapeutics – Key market restraint analysis
8. Side effects, by class
9. Dosage information: IVIG and IVIG with high dose methylprednisolone
10. Comparative analysis: Dexamethasone and Dexamethasone with rituximan
11. Impact of splenectomy on product segments
12. List of major brands and generic names of corticosteroids for ITP
13. Brands and generic names of IVIG for ITP
14. List of major brands and generic names of anti-D for ITP
15. North America ITP therapeutics market, by product, 2012 – 2020 (USD Million)
16. U.S. ITP therapeutics market, by product, 2012 – 2020 (USD Million)
17. Mexico ITP therapeutics market, by product, 2012 – 2020 (USD Million)
18. Access to orphan drugs in European countries (key countries)
19. Europe ITP therapeutics market, by product, 2012 – 2020 (USD Million)
20. Germany ITP therapeutics market, by product, 2012 – 2020 (USD Million)
21. U.K ITP therapeutics market, by product, 2012 – 2020 (USD Million)
22. Asia Pacific ITP therapeutics market, by product, 2012 – 2020 (USD Million)
23. India ITP therapeutics market, by product, 2012 – 2020 (USD Million)
24. Japan ITP therapeutics market, by product, 2012 – 2020 (USD Million)
25. China ITP therapeutics market, by product, 2012 – 2020 (USD Million)
26. Brazil ITP therapeutics market, by product, 2012 – 2020 (USD Million)
LIST OF FIGURES
1. ITP Therapeutics: Market Segmentation
2. Global ITP therapeutics market, 2012 – 2020 (USD Million)
3. ITP Therapeutics market dynamics
4. Key Opportunities Prioritized
5. ITP Therapeutics market – Porter’s analysis
6. ITP Therapeutics market – PESTEL analysis
7. ITP therapeutics market share by product, 2013 & 2020
8. Global corticosteroids for ITP market, 2012 – 2020 (USD Million)
9. Global IVIG for ITP market, 2012 – 2020 (USD Million)
10. Global anti-D for ITP market, 2012 – 2020 (USD Million)
11. Global TPO-RA for ITP market, 2012 – 2020 (USD Million)
12. Global other therapies for ITP market, 2012 – 2020 (USD Million)
13. ITP therapeutics market share, by region, 2013 & 2020
14. North America ITP therapeutics market , 2012 – 2020 (USD Million)
15. Europe ITP therapeutics market , 2012 – 2020 (USD Million)
16. Asia Pacific ITP therapeutics market , 2012 – 2020 (USD Million)
17. RoW ITP therapeutics market , 2012 – 2020 (USD Million)
1. ITP Therapeutics: Market Segmentation
2. Global ITP therapeutics market, 2012 – 2020 (USD Million)
3. ITP Therapeutics market dynamics
4. Key Opportunities Prioritized
5. ITP Therapeutics market – Porter’s analysis
6. ITP Therapeutics market – PESTEL analysis
7. ITP therapeutics market share by product, 2013 & 2020
8. Global corticosteroids for ITP market, 2012 – 2020 (USD Million)
9. Global IVIG for ITP market, 2012 – 2020 (USD Million)
10. Global anti-D for ITP market, 2012 – 2020 (USD Million)
11. Global TPO-RA for ITP market, 2012 – 2020 (USD Million)
12. Global other therapies for ITP market, 2012 – 2020 (USD Million)
13. ITP therapeutics market share, by region, 2013 & 2020
14. North America ITP therapeutics market , 2012 – 2020 (USD Million)
15. Europe ITP therapeutics market , 2012 – 2020 (USD Million)
16. Asia Pacific ITP therapeutics market , 2012 – 2020 (USD Million)
17. RoW ITP therapeutics market , 2012 – 2020 (USD Million)
